http://orcid.org/0000-0002-3487-2240
References
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387:1513–1530.
- Malanda B, Karuranga S, Saeedi P, et al., editors; International Diabetes Federation. IDF diabetes atlas. 9th ed. Brussels (Belgium): International Diabetes Federation; 2019.
- Chen S, Kuhn M, Prettner K, et al. The macroeconomic burden of noncommunicable diseases in the United States: estimates and projections. PLoS One. 2018;13:e0206702.
- Hayes A, Arima H, Woodward M, et al. Changes in quality of life associated with complications of diabetes: results from the ADVANCE study. Value Health. 2016;19:36–41.
- American Diabetes Association. Economic costs of diabetes in the U.S. in 2017. Diabetes Care. 2018;41:917–928.
- Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–149.
- Chapman D, Foxcroft R, Dale-Harris L, et al. Insights for care: the healthcare utilisation and cost impact of managing type 2 diabetes-associated microvascular complications. Diabetes Ther. 2019;10:575–585.
- Hex N, Bartlett C, Wright D, et al. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29:855–862.
- Einarson TR, Acs A, Ludwig C, et al. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018;17:83
- Einarson TR, Acs A, Ludwig C, et al. Economic burden of cardiovascular disease in type 2 diabetes: A systematic review. Value Health. 2018;21:881–890.
- Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41:1–69.
- American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S111–S134.
- American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S98–S110.
- Conselho Nacional de Saúde. Resolução No 510, de 07 de Abril de 2016. 2016 [accessed 2019 Nov]. Available from: http://conselho.saude.gov.br/resolucoes/2016/reso510.pdf
- Campos DF, Rosim RP, Duva AS, et al. Brazilian healthcare record linkage (brhc-rlk) – a record linkage methodology for Brazilian medical claims datasets (DATASUS). Value Health. 2017;20:A321.
- DataSUS. The SUS table of procedures, medications and orthoses, prostheses and special materials (OPM) (SIGTAP). 2019 Oct. Available from: http://www.sgc.goias.gov.br/upload/links/arq_961_tabelacompleta.pdf
- Jacobs MS, van Leent MWJ, Tieleman RG, et al. Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in The Netherlands. J Med Econ. 2017;20:1231–1236.
- Bahia LR, Araujo DV, Schaan BD, et al. The costs of type 2 diabetes mellitus outpatient care in the Brazilian public health system. Value Health. 2011;14:S137–S140.
- Williams R, CODE-2 Advisory Board, Van Gaal L, Lucioni C. Assessing the impact of complications on the costs of Type II diabetes. Diabetologia. 2002;45:S13–S17.
- Chen D, Liu S, Tan X, et al. Assessment of hospital length of stay and direct costs of type 2 diabetes in Hubei Province. BMC Health Serv Res. 2017;17:199.
- Bahia LR, da Rosa MQM, Araujo DV, et al. Economic burden of diabetes in Brazil in 2014. Diabetol Metab Syndr. 2019;11:54
- The World Bank. GDP (current US$) – Brazil. 2014. [accessed 2017 Apr]. Available from: https://data.worldbank.org/indicator/NY.GDP.MKTP.CD?locations=BR
- Bertoluci MC, Moreira RO, Faludi A, et al. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr. 2017;9:53.